Stockreport

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

Rhythm Pharmaceuticals, Inc.  (RYTM) 
Last rhythm pharmaceuticals, inc. earnings: 3/8 08:12 am Check Earnings Report
US:NASDAQ Investor Relations: ir.rhythmtx.com
PDF -- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway -- -- RM-718 showed potential to reduce body weight and hyperphagia, no hyperpi [Read more]